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Rote of IL-lji and prostaglandins in 2.microglobulin-induced bone
mineral dissolution. 32-microglobulin (g32m) induces an osteoclast-medi-
ated net calcium efflux from neonatal mouse calvariac which occurs only
after 48 hours of incubation, suggesting that 2m acts via other growth
factors. To further test this hypothesis, calvariae were incubated with and
without 2m in the presence of the prostaglandin inhibitor indomethacin,
aoti-interleukin-13 antibody (anti-IL-1/3), or interleukin-13 receptor an-
tagonist (IL-1f3 RA). The addition of /32m to the culture medium
stimulated, whereas indomethacin inhibited basal calcium efflux following
48 hours. However, the difference (delta) between the calcium efflux
induced in calvariae incubated with and without 2m in basal medium and
that in calvariae incubated with and without f32m in indomethacin
supplemented medium was similar, suggesting a prostaglandin indepen-
dent mechanism. There was a time dependent increase in PGE2 in basal
medium which was unaffected by 2m. In contrast, pre-incubating cal-
variae with either anti-IL-1$ or IL-13 RA did not alter basal calcium efflux
but completely blocked the ,82m induced calcium efflux. Anti-IL-1f3 had no
effect on the basal release of /3-glucuronidase but partially blocked the
/32m induced release of 3-glucuronidase. Thus, the f32m-induced calcium
efflux observed in neonatal mouse calvariae is dependent on interleu-
kin-1/3 but not prostaglandins.
)32-microglobulin (f32m) amyloidosis is a destructive osteoar-
ticular disease that affects patients undergoing long-term dialytic
therapy. f32m has a molecular weight of 11,800 Da and serum
concentrations of f32m are elevated 20- to 50-fold in chronic
dialysis patients. The protein can deposit as a component of
p-pleated amyloid sheets resulting in bone cyst formation and
erosive skeletal and periartieular disease [1]. Whether 2m is
directly involved in this bone destruction or is merely a compo-
nent of the amyloid deposits is unknown. Recent evidence sug-
gests that f32m may have a physiologic role in bone remodeling.
2m is homologous to bone-derived growth factor (BDGF) [2]
and is mitogenie to isolated osteoblasts [2—4], suggesting a role in
bone formation. Previously we have demonstrated that f32m
induces a dose-dependent net calcium efflux from cultured neo-
natal mouse calvariae [5, 6]. This net calcium efflux is due, at least
in part, to osteoclastic stimulation. 2m stimulated the release of
the osteoclastic enzyme f3-glucuronidase and both the calcium
efflux and f3-glucuronidase release was inhibited by ealcitonin.
32m induced calcium efflux and release of J3-glueuronidase oc-
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curred only after 48 hours of incubation, suggesting that f32m may
act via the stimulation or inhibition of other bone growth factors
[5, 6]. Supporting the hypothesis that 132m interacts with other
bone growth factors is a report demonstrating that f32m enhances
receptor number and gene transcription of insulin-like growth
factor I (IGF I) [3].
Various growth factors play a regulatory role in the control of
bone remodeling. Both interleukin-1 [IL-i], previously referred to
as osteoclast activating factor [7], and prostaglandin E2 (PGE2)
have multiple effects on bone. IL-la and IL-1/3 are produced by
neonatal mouse calvariae [8, 9] and have similar physiologic
effects [9]. IL-i stimulates bone resorption in vitro [10—12], in vivo
[13, 14] and produces hypercalcemia when injected into normal
mice [15]. PGE2 also stimulates bone resorption in vitro [16, 17]
and in vivo [18]. To determine if 32m may interact with these
known bone resorptive growth factors, the effect of prostaglandin
and IL-1/3 inhibition on /32m induced calcium efflux in the
neonatal mouse calvariae culture system was evaluated.
Methods
Organ culture of bone
Neonatal (4- to 6-day-old) CD-i mice (Charles River, Portage,
MI, USA) were killed by cervical dislocation, their calvariae
removed by dissection, and two ealvariae were placed on a
stainless steel wire grid in culture media as previously described
[5, 6, 19]. Baseline media and final media were analyzed as
detailed below and ealvariae were incubated for 3 to 48 hours.
Experimental and control cultures were performed in parallel and
random order, and the data presented in each figure and table
represent a minimum of three independent experiments to
achieve the number of pairs of ealvariae in each group.
Experimental conditions
Calvariae were cultured with and without f32m at io M, a
concentration previously shown to maximally stimulate calcium
efflux and p-glucuronidase release from cultured neonatal mouse
ealvariae [5, 6]. /32m was added to the medium in a constant
volume to achieve the desired final concentrations. For the
prostaglandin experiments, 2m was purchased from Sigma
Chemicals (St. Louis, MO, USA). For the interleukin-if3 (IL-if3)
experiments the 2m was isolated from dialysate ultrafiltrate from
a patient with acute renal failure undergoing continuous hemo-
filtration. The ultrafiltrate was concentrated, lyophilized and
dissolved in 0.01 M Tris-HCI, pH 7.8. The solution was then
applied to an anion exchange column (DE-52, Whatman mt. Ltd,
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Fig. 1. SDS-PAGE and Western blot analysis of J32rn. A and B represent
analysis of denatured proteins on 10 to 20% gradient gel; C and D
represent Western blot analysis of identical gels. A. Lane 1 is 132m isolated
from human dialysate ultrafiltrate, lane 2 is human rIL-1f3, (mixed 50:1 in
BSA by manufacturer). C is the blot of A incubated with mouse
anti-human rIL-1J3 Ab indicating no contamination of (32m with IL-1/3.
Similar results were obtained with Sigma j32m. B shows Sigma 132m in lane
3 and j32m isolated from human dialysate ultrafiltrate in lane 4. D is the
blot of B incubated with mouse anti-human 2m Ab demonstrating the
presence of both monomers and dimers of /32m.
Maidstone, UK) and eluted with a 0 to 0.15 M NaCI gradient. The
fractions were analyzed with an ELISA to (32m (Kabi Pharmacia
Diagnostics, Piscataway, NJ, USA) and the 132m fraction further
purified via gel filtration. Both the isolated human f32m and Sigma
human J32m were analyzed with a 10 to 20% gradient ready-gel
(Biorad, Hercules, CA, USA; Fig. 1). Duplicate gels were trans-
ferred to a nitrocellulose membrane, blocked and then exposed to
either a polyclonal rabbit anti-human IgG to f32m (Boehringer
Mannheim, Indianapolis, IN, USA) or rabbit anti-human rIL-1f3
(Sigma). The latter was to confirm no contamination of either
(32m with IL-I /3. The Western blots were further reacted with goat
anti-rabbit IgG and developed with 4-chloro-I -napthol solution.
The isolated 132m and Sigma 132m yielded similar results by PAGE
and Western blot analysis (Fig. 1). Subsequent studies comparing
the effects of the two sources of 132m in the neonatal mouse
calvariae model yielded equivalent results and therefore in some
experiments the results were combined.
To determine if /32m-induced calcium efflux was mediated via
prostaglandin stimulation, some calvariae were incubated with or
without the prostaglandin inhibitor indomethacin (106 Sig-
ma). To determine if j32m-induced calcium efflux was mediated via
IL-1f3, calvariae were pre-incubated for three hours with or
without anti-murine interleukin-1f3 neutralizing antibody at iO
M (anti-IL-1/3; R and D Systems, Minneapolis, MN, USA) or a
murine interleukin-1f3 receptor antagonist at 10—8 M (IL-1/3 RA;
R and D Systems) prior to the addition of 132m. For comparison,
calvariae were incubated in the presence of recombinant human
IL-113 (10— 12 M R and D Systems) or normal goat serum (Sigma).
Analytical measurements
Calcium flux. Total calcium was determined by automatic
fluorometric titration (Calcette, Precision Systems, Sudbury, MA,
USA) [5, 6, 19]. Net calcium flux (Ja) was calculated as Vm(Cf —
C) where Vm is the medium volume (2 ml) and C and C. are the
final and initial calcium concentrations, respectively, in nmol/ml
[5, 6, 19]. A positive flux (efflux) indicates movement of calcium
from bone into medium, and a negative flux (influx) indicates the
movement of calcium from medium into bone.
Prostaglandin E PGE2 was measured using an RIA with 125j
(New England Nuclear, Boston, MA, USA). Following incubation
of calvariae, medium was immediately removed and stored at
—70°C until analysis.
f3-glucuronidase. /3-glucuronidase release is indicative of oste-
oclast bone resorption [20] and correlates with calcium efflux [5, 6,
19]. /3-glucuronidase activity was determined using a modification
of the assay described by Fishman et al (Sigma) [5, 6, 19, 21].
Immediately following the experimental culture period, an aliquot
of medium was incubated (1 hr, 56°C) with 0.03 M phenolphtha-
lein mono-(3-glucuronic acid and 0.2 M acetate buffer. The reac-
tion was terminated by adding 0.1 M 2-amino-2-methyl-1 propanol
buffer and the amount of phenolphthalein released measured
spectrophotometrically at 550 nm. j3-glucuronidase activity was
calculated as g of phenolphthalein released per bone per hour
and expressed as percent of control activity.
Statistical analysis
Regressions were calculated by least square analysis, and group
means were compared with analysis of variance using conven-
tional statistical programs (Instat, San Diego, CA, USA) written
for a personal computer. All values are expressed as mean SE;
P < 0.05 is considered significant.
Results
Role of prostaglandins in f32-microglobulin-induced bone
resorption
Compared to control, the addition of (32m to the culture
medium induced a net calcium efflux from bone following a 48
hours of incubation (/32m = 564.05 59.97; Control = 380.27
49.22 nmol/bone/48 hr; P < 0.03; Fig. 2). The addition of
indomethacin, a prostaglandin inhibitor, inhibited the basal cal-
cium efflux from neonatal calvariae (indomethacin; Indo = 13.56
29.92 nmol/bone/48 hr; P < 0.001 vs. control; Fig. 2). The
addition of indomethacin to medium supplemented with (32m ap-
peared to block the /32m-induced calcium efflux (P < 0.001; Fig. 2).
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Fig. 2. Effect of prostaglandin inhibition on l32m-induced calcium efflux in
neonatal mouse calvariae incubated for 48 hours. Values represent mean
SE for 10 to 13 pairs of calvariae per group. Calvariac were incubated in
control medium, medium supplemented with 132m (l0 M), medium
supplemented with indomethacin (Indo; 10_6 M), or f32m plus indometha-
cm and net calcium flux determined. Compared to control, the addition of
j32m induced a net calcium eftIux whereas indomethacin inhibited basal
calcium efflux. The addition of indomethacin to medium supplemented
with 32m appeared to block the f32m-induced calcium efflux. However, the
difference (delta = A) between the calcium efflux induced in ealvariae
incubated with and without j32m in basal medium and the delta calcium
flux induced in calvariae incubated with and without f32m in indomethacin
supplemented medium was similar. Thus, 132m-induced calcium efflux is
prostaglandin independent. Symbols are: * different from Control;
+ different from 132m; o different from indomethacin, all P C 0.03.
However, the difference (delta = A) between the calcium efliux
induced in calvariae incubated with and without /32m in basal
medium and the A calcium flux induced in calvariae incubated with
and without /32m in indomethacin supplemented medium was similar
(187.14 83.65; 171.94 60.73 nmollbone/48 hr, respectively, Fig.
2). Thus, indomethacin inhibited basal calcium efflux but did not
affect the calcium efilux induced by /32m.
To confirm that f32m-induced calcium efflux was not prosta-
glandin dependent and to exclude the potential stimulation of
prostaglandins by j32m at shorter incubations, the release of
POE2, the most abundant and one of the most potent bone
resorbing porstaglandins [16, 17, 201 was measured. POE2 levels
were increased in basal medium following 3, 24, and 48 hours with
a peak effect observed after a 24 hour incubation (Fig. 3). The
addition of f32m did not affect this basal POE2 release following
incubation for 3, 24, or 48 hours (Fig. 3). The release of POE2 at
48 hours was, as expected, inhibited by indomethacin (Indo
28.63 8.58; Control 154.37 38.30 pg/ml, P < 0.05; Fig. 3).
Thus, f32m-induced calcium efflux in neonatal mouse calvariae is
prostaglandin independent.
Role of interleukin-113 in 32-microglobulin induced bone
resorption
Compared to control, the addition of f32m to the culture
medium induced a net calcium efflux from bone following a 48
hour incubation (/32m = 499.73 73.79; Control = 209.99
39.52 nmollbone/48 hr; P < 0.01; Fig. 4). Pre-incubating calvariae
with anti-IL-I f3 did not alter basal calcium efflux (anti-IL-1/3 =
150.95 54.80 nmollbone/48 hr; Fig. 4), but completely blocked
the f32m-induced calcium efflux (anti-IL-1/3 + /32m = 224.42
Fig. 3. Effect of (32m on prostaglandin E2 (PGE2) production in neonatal
mouse calvariae incubated for 3 to 48 hours. Values represent mean sa for
6 to 9 pairs of calvariae per group. Calvariae incubated in control medium (U)
showed a time dependent increase in POE2 production, peaking at 24 hours.
The addition of /32m (; i0 M) did not alter the release of POE2.
Indomethaein (; iO M) inhibited the release of POE2. Thus, (32m did not
alter the basal release of POE with time. Symbols are: * different than time
0 hr, same treatment; different than time 3 hi, same treatment; o =
different than time 24 hi, same treatment; ** different than control, same
time; + + different than f32m same time; all P C 0.05).
Fig. 4. Effect of murine interleukin-1f3 antibody (anti-IL-i /3) on f32m in-
duced calcium efflux in neonatal mouse calvariae incubated for 48 hr. Values
represent mean SE for 8 to 17 pairs of calvariae per group. Symbols are:
(U) calvariae incubated in control medium, medium supplemented with
/32m (10 M), or media supplemented with rIL-1/3 (1012 M); ()
ealvariae pre-ineubated with anti-IL-1f3 (10 M) prior to incubation with
control media, media supplemented with /32m or media supplemented
with IL-1/3, Compared to control, the addition of /32m or IL-1/3 induced a
net calcium efflux. Incubation of calvariae with anti-IL-1/3 did not affect
basal calcium efflux, but inhibited both f32m and IL-1/3-induced calcium
efflux. Thus, i32m-induced calcium efliux is dependent on IL-1/3. Symbols
are: * different than control without IL-1/3 Ab; + different than control
with IL-1f3 Ab; all P C 0.05).
53.32; P C 0.04 vs. /32m; Fig. 4). Incubating the calvariae in the
presence of rIL-1j3 led to a net calcium efflux similar in magnitude
to that induced by /32m (555.50 73.02 nmollbone/48 hr; P C 0.05
vs. control; P = NS vs. f32m). Pre-incubating the calvariae with
anti-IL-I /3 completely blocked the effects of rIL-1/3 (anti-IL-1/3 +
rIL-1/3 = 175.23 58.42 nmol/bone/48 hr; P C 0.05 vs. rIL-I/3
alone; P = NSvs. anti-IL-Q alone or j32m + anti-IL-1/3; Fig. 4). In
contrast, incubating control medium, or medium supplemented
with /32m or rIL-I /3 in the presence of 0.5% pre-immune goat
6OO 200
500 a)o 150to
+ 100
a
0)& 50
0
Control [3,m Anti-lL-1 j32ni &
lL-13 PA 32m &
Anti-lL-1
IL-1f3 PA
200
400
300
+
100
0
Control
590 Moe et al: IL-1/3 and prostaglandins in /32m bone loss
Fig. 5. Effect of /32m and murine IL -1 /3 receptor antagonist (IL-i/3 RA) on
f32m-induced calcium efflux in neonatal mouse calvariae incubated for 48 hr.
Values represent mean SE for 6 to 12 pairs of calvariae per group.
Compared to control, /32m (10-v M) induced a net calcium efflux.
Pre-incubating the calvariae with IL-i /3 RA (IL-113 RA) had no effect on
basal calcium efflux but completely blocked the efflux induced by f32m
(/32m + IL-113 RA). Thus, /32m-induced calcium efflux is directly mediated
by IL-i/3. Symbols are: * different than control; + different than /32m; both
P < 0.02.
anti-mouse IgG had no effect (Control + IgG = 141.40 83.28,
f32m + IgG = 406.35 84.35, rIL-1/3 + IgG = 626.6 81.47; all
P = NS vs. without IgG). Thus the magnitude of calcium efflux
induced by /32m is similar to that induced by IL-1f3 and the effects
of both can be blocked by a neutralizing anti-IL-1/3 Ab.
To determine if IL-1f3 is simply a co-factor necessary for the
effects of f32m or a direct mediator, calvariae were pre-incubated
with and without IL-1/3 RA. Pre-incubating the calvariae in IL-1f3
RA did not alter basal calcium efflux (IL-i RA = 214.14 78.48;
Control 195.71 54.25 nmollbone/48 hr; P = NS; Fig. 5) but
completely blocked the /32m-induced calcium efflux (/32m =
517.56 62.86; f32m + IL-i/3 RA = 285.87 45.38 nmol/bone/48
hr; P < 0.02; Fig. 5). Therefore, the effects of 132m are directly
dependent on IL-1.
To determine whether IL-1f3 interferes with /32m osteoclastic
stimulation, the production of 3-glucuronidase, an osteoclastic
lysosomal enzyme, was measured. Compared to control, the
release of /3-glucuronidase was significantly increased by the
addition of /32m (/32m 158.67 20.83% control, P < 0,02; Fig. 6).
Pre-incubation of calvariae with anti-IL-1/3 had no effect on the
basal release of f3-glucuronidase (anti-IL-113 = 105.14 4.89%
control) but partially blocked the f32m induced release of f3-gluc-
uronidase (anti-IL-1f3 + f32m 121.14 16.91% Control; Fig. 6).
This suggests that 2m induced stimulation of osteoclast activity
is, in part, dependent on IL-1f3.
Discussion
Neonatal mouse calvariae contain functioning osteoclasts and
osteoblasts and respond to hormones and other maneuvers as
does human bone in vivo, and therefore is an appropriate in vitro
model to study the effects of /32m on bone. We have previously
demonstrated that f32m induces a dose-dependent net calcium
efflux from neonatal mouse calvariae that requires a 48 hour
incubation and involves the stimulation of osteoclasts [5, 6]. This
study demonstrates that this calcium efflux can be inhibited by
Fig. 6. Effect of /32m and murine interleukin-1/3 antibody (anti-IL-i /3) on
the release of the osteoclastic enzyme, f3-glucuronidase, in neonatal mouse
calvariae incubated for 48 hr. Values represent mean SE for 8 to 10 pairs
of calvariae per group. Compared to control, the addition of /32m (10—v M)
led to a release of /3-glucuronidase. Pre-incubation of calvariae with
anti-IL-1f3 (10—p M) did not affect basal 13-glucuronidase release. Pre-
incubation of calvariae with anti-IL-113 prior to the addition of j32m
partially inhibited /32m induced release of /3-glucuronidase. Thus, /32m
induced osteoclastic stimulation, as measured by the release of /3-glue-
uronidase, may be partially IL-if3 dependent. Symbols are: * different than
control; + different than /32m; both P < 0.02.
both neutralizing anti-IL-1J3 antibody and IL-113 receptor antag-
onist, suggesting that 132m calcium efflux is directly mediated by
IL-1/3. In contrast, incubating the calvariae with 132m in the
presence of indomethacin, a prostaglandin inhibitor, had no net
effect on 132m-induced calcium efflux. /32m did not stimulate the
release of PGE2 at 3, 24 or 48 hours, further supporting a
prostaglandin independent mechanism.
Net calcium efflux can result from increased osteoclastic bone
resorption, decreased osteoblastic bone formation and/or an
uncoupling of bone resorption from bone formation. We have
previously found that /32m-induced bone mineral dissolution from
neonatal mouse calvariae was associated with the release of
f3-glucuronidase, an osteoclastic enzyme, and was inhibited by
calcitonin suggesting osteoclast involvement [5, 6]. Several studies
have demonstrated that IL-i induces a net calcium efflux from
cultured mouse calvariae [10, 11, 12, 22], a process inhibited by
calcitonin and therefore mediated by osteoclasts [22]. Utilizing an
antibody to IL-lp, this present study demonstrated a complete
blockade of /32m-induced calcium efflux, but only partial inhibition
in the release of the osteoclastic enzyme, 13-glucuronidase. These
results suggest that p2m-induced calcium efflux is not only depen-
dent upon osteoclast resorption, but may also involve the inhibi-
tion of bone formation and/or an uncoupling of bone formation
from resorption. In addition, [32m interacts with other bone growth
factors [3] further complicating the interpretation of these results.
We were unable to demonstrate a stimulation of PGE2 release
during the incubation period, consistent with data from Evans,
Thavarajah and Kanis, who could not demonstrate any release of
PGE2 from isolated human osteoblasts that were stimulated with
J32m [4J. This is somewhat surprising as prostaglandins are in-
volved in the bone resorption induced by many growth factors
including epidermal growth factor, transforming growth factor,
and tumor necrosis factor [231. However, studies evaluating the
release of PGE2 from IL-i stimulated bone organ culture have
yielded conflicting results. In cultured mouse calvariae, one group
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has demonstrated IL-i-induced bone resorption to be prosta-
glandin independent [ii], whereas other have demonstrated
inhibition of IL-i-induced calcium efflux with indomethacin [12].
This may be due in part to the complicated action of prostaglan-
dins in bone. Garrett and Mundy have clarified the issue by
demonstrating that the initial osteoclast recruitment that occurs in
the pre-incubation period was prostaglandin dependent and IL-1f3
maintained the osteoclast number thereafter, in a non-prosta-
glandin dependent mechanism [24]. This study evaluated osteo-
clast activity as measured by the release of f3-glucuronidase;
whether 32m also affects osteoclast recruitment is unknown.
IL-i is important in the pathogenesis of the joint destruction
observed in rheumatoid arthritis and is found in excess in the
synovial fluid of patients with active disease [25]. Interestingly, the
clinical presentation of f32m amyloidosis is similar to that of
destructive rheumatoid arthritis, a subtype of classical rheumatoid
arthritis [25]. Tenosynovium obtained from patients with f32m
amyloidosis and carpel tunnel syndrome contain IL-i and IL-6 by
immunohistochemical staining and IL-i and IL-6 activity in the
culture supernatant [26]. Miyata et al recently demonstrated that
some of the f32m isolated from long-term dialysis patients was
altered with advanced glycation end products (AGE; [27]) and
that the AGE-2m induced the release of IL-if3 from human
macrophages [28]. However, whether this was an effect of the 2m
or an effect of AGE was not clear as other proteins altered with
AGE also induce the release of IL-i [29]. The present studies
provide in vitro evidence that J32m-induced bone resorption is
mediated through IL-if3. Whether the finding of IL-i in amyloid
deposits correlates with bone destruction in vivo and the precise
cellular mechanism by which this may occur requires further study.
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